Jefferies Financial Group Inc. Buys New Stake in InflaRx N.V. $IFRX

Jefferies Financial Group Inc. bought a new stake in InflaRx N.V. (NASDAQ:IFRX) in the 2nd quarter, HoldingsChannel reports. The fund bought 775,349 shares of the company’s stock, valued at approximately $1,737,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. ADAR1 Capital Management LLC acquired a new position in shares of InflaRx during the second quarter worth $6,720,000. Spruce Street Capital LP acquired a new stake in shares of InflaRx in the 2nd quarter worth $11,988,924. Sanctuary Advisors LLC acquired a new stake in InflaRx in the second quarter worth about $25,000. DCF Advisers LLC purchased a new stake in shares of InflaRx during the second quarter worth about $512,000. Finally, XTX Topco Ltd purchased a new stake in shares of InflaRx during the fourth quarter worth about $135,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Trading Down 1.8%

Shares of IFRX opened at $2.23 on Friday. The business’s 50 day moving average is $1.99 and its 200 day moving average is $1.65. InflaRx N.V. has a 12-month low of $0.80 and a 12-month high of $2.95. The company has a market capitalization of $328.64 million, a PE ratio of -3.84 and a beta of 2.48.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). Equities research analysts predict that InflaRx N.V. will post -0.31 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Zacks Research lowered shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 25th. HC Wainwright boosted their target price on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $7.00 to $9.00 in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.33.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.